Literature DB >> 14675308

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5.

M A Bookman1, B E Greer, R F Ozols.   

Abstract

Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14675308     DOI： 10.1111/j.1525-1438.2003.13602.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN： 1048-891X            Impact factor:   3.437


  23 in total

Review 1.  A terrible beauty: a physician's story of ovarian cancer.

Authors:  Linda J Spano
Journal:  Can Fam Physician       Date:  2007-06       Impact factor: 3.275

Review 2.  Survivorship as an element of clinical trials in ovarian cancer.

Authors:  Jessica N McAlpine; Lari B Wenzel
Journal:  Int J Gynecol Cancer       Date:  2011-05       Impact factor: 3.437

3.  Clinical and prognostic value of the presence of irregular giant nuclear cells in pT1 ovarian clear cell carcinoma.

Authors:  Naoki Matsumoto; Takashi Umezawa; Toru Sasaki; Kuninobu Nakajima; Yukiko Kanetsuna; Hiroshi Sasaki
Journal:  Pathol Oncol Res       Date:  2011-01-28       Impact factor: 3.201

4.  Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer.

Authors:  Takehiko Segawa; Toshiyuki Kamoto; Hidefumi Kinoshita; Yasuharu Kunishima; Koji Yoshimura; Akihiro Ito; Takeshi Takahashi; Shin Higashi; Eijiro Nakamura; Hirofumi Nishiyama; Noriyuki Ito; Shingo Yamamoto; Tomonori Habuchi; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

5.  Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.

Authors:  Dana M Chase; Helen Huang; Cassandra D Foss; Lari B Wenzel; Bradley J Monk; Robert A Burger
Journal:  Gynecol Oncol       Date:  2014-12-18       Impact factor: 5.482

6.  Ovarian cancer survival by tumor dominance, a surrogate for site of origin.

Authors:  Anna Ivanova; Anneli Loo; Shelley Tworoger; Christopher P Crum; Isabel Fan; John R McLaughlin; Barry Rosen; Harvey Risch; Steven A Narod; Joanne Kotsopoulos
Journal:  Cancer Causes Control       Date:  2015-03-13       Impact factor: 2.506

7.  Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer.

Authors:  Won Deok Joo; Ji Young Lee; Jong Hyeok Kim; Hang Jo Yoo; Hyun Jin Roh; Jeong-Yeol Park; Dae-Yeon Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2009-06-29       Impact factor: 4.401

Review 8.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

9.  Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.

Authors:  Masashi Takano; Toru Sugiyama; Nobuo Yaegashi; Mitsuaki Suzuki; Hiroshi Tsuda; Satoru Sagae; Yasuhiro Udagawa; Kazuo Kuzuya; Junzo Kigawa; Satoshi Takeuchi; Hitoshi Tsuda; Takuya Moriya; Yoshihiro Kikuchi
Journal:  Int J Clin Oncol       Date:  2007-08-20       Impact factor: 3.402

Review 10.  Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Authors:  Theresa A Lawrie; Andrew Bryant; Alison Cameron; Emma Gray; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2013-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.